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Abstract
Endovascular aneurysm repair is associated, in a significant proportion of patients, 
to a systemic  inflammatory response denominated postimplantation syndrome 
(PIS). PIS is characterized by fatigue, fever, and a rise in inflammatory biomarkers 
after the operation. However, the exact definition is still a matter of debate. There 
are several proposed definitions for PIS in the literature resulting in significant vari-
ability of PIS incidence (ranging from 2% to 100%). The etiology of PIS is not entirely 
clear. Endograft composition, aortic thrombus, intestinal bacterial translocation, and 
contrast media may contribute to PIS but the first seems to be the most important 
determinant. This clinical entity may have clinical consequences in length of hospital 
stay, readmissions, renal function, cardiovascular events, endoleak rate, and quality 
of life, but current data are insufficient for definitive conclusions. Despite of absence 
of stablished treatment for PIS, non-steroid and steroid anti-inflammatory drugs 
are currently advocated when clinical suspicion arises. Prevention may be achieved 
with perioperative administration of a steroid drug. Since it may have adverse 
effects, further knowledge of the real incidence of PIS and its clinical consequences 
is imperative.
Keywords: inflammation, inflammatory response syndrome, systemic, foreign-body 
reaction, aneurysm, aortic aneurysm, abdominal, aortic aneurysm, thoracic, endovascular 
procedures
1. Introduction
Endovascular aneurysm repair is associated, in a significant proportion of cases, to a systemic 
inflammatory response that was denominated Postimplantation syndrome (PIS) [1]. PIS was 
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first described in 1999 by Velazquez et al. [2] as a syndrome of fever and leukocytosis after 
aortic stent-graft implantation. It was incidentally noted in prior clinical studies on EVAR, 
but the exact origin is unknown. The authors suggested that these manifestations, comprising 
fatigue or other constitutional (flu-like) symptoms, fever and laboratory findings of inflam-
mation, are a reproducible phenomenon specific to the nature of this procedure, rather than 
related to postoperative infections [2].
In fact, experimental studies in animals had suggested a local peri-aortic inflammatory 
response to endovascular exclusion of aneurysms. For example, in a study in sheep that under-
went to endovascular implantation of heparin-coated Dacron-covered grafts, the macroscopic 
examination of the arterial wall revealed significant inflammatory peri-graft response with 
vascular thickening and adhesions around the grafts. Microscopic examination revealed a 
severe foreign-body response [3].
Several publications addressing the issue have been published since 1999. However, there is 
still no consensus over the definition for the syndrome, its real incidence, associated factors, 
consequences, treatment, and eventually prophylactic therapy.
2. Definition and incidence
PIS is defined as fatigue and fever associated to a rise in inflammatory biomarkers. Which 
markers should be used and their cutoff values is still a matter of debate. There are several 
proposed combinations of fever, leukocytosis, and elevated C-reactive protein (CRP) used as 
definition for PIS in the literature. Some authors defined PIS as the presence of fever coincid-
ing with an elevated serum CRP level, whereas the majority of them adapted the systemic 
inflammatory response syndrome (SIRS) criteria and defined PIS as the presence of fever 
combined with leukocytosis [1, 2, 4–11].
Arnaoutoglou et al. [10] defined PIS as the presence of fever (>38°C) and leukocytosis (>12.000/μL). 
However, they verified that hs-CRP values were strongly related to the presence of PIS and 
also emerged as an important predictor of the 30 day-outcome. Therefore, they concluded 
that hs-CRP probably is a better marker to inflammatory response. The reported incidence of 
PIS in the literature varies widely, and the lack of a universally accepted definition may be 
responsible for this. Reported incidence ranges from 2 to 100% (Table 1).
Blum et al. [12], analyzed prospectively the clinical outcome after EVAR in 154 patients. 
All were treated with polyester-covered nitinol endograft and 87 patients (56%) developed 
fever (temperature, 38.0–39.7°C), that lasted for 4–10 days, without evidence of bactere-
mia or graft infection. All patients showed leukocytosis (range from 9.800 to 29.500/μL) 
in laboratory tests and an elevation of C-reactive protein concentrations (range from 4 to 
34.1 mg/dL) [12].
Two years after, Velazquez et al. [2] developed the first study specifically aimed at describing 
and understanding the postimplantation syndrome, characterized by fever and leukocytosis 
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following endovascular stent graft repair of aortic aneurysms. They defined PIS as a syn-
drome that occurs after EVAR and proposed two criteria for diagnosis: fever and leukocy-
tosis. However, the cutoffs of these criteria are not specified. In their small study, they found 
seven patients (58%) to have leukocyte count superior to 11.000/μL, 10 patients (83%) to have 
fever greater than 38°C and 8 patients (67%) superior to 38.5°C. Indeed, in eight patients, CT 
revealed air within the native aorta, around the stent-graft and within the thrombus of the 
*Only with Incraft® endograft.
**Only with Zenith Alpha® thoracic endografts.
*** The sample only included percutaneous EVAR.
****Only with Anaconda® endograft.
aThis group defined PIS as fever and leukocytosis and abdominal and/or back pain, or other nonspecific symptoms such 
as malaise or loss of appetite.
Table 1. Incidence of PIS according to definition.
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excluded aneurysm. Physical examination, chest radiograph, urinalysis, urine culture and 
blood culture excluded any source of infection in 11 of 12 patients [2].
Gabriel et al. [13] analyzed the inflammatory response after endovascular repair of abdomi-
nal, thoracic and thoracoabdominal aortic aneurysms, but they neither define PIS nor stated 
its incidence. They found that peak values of sedimentation velocity, CRP and interleukin-6 
were observed at 7 postoperative days, elevation of leukocytes count occurred in premature 
phase, while lymphocyte and platelet count occurred in a late phase of follow-up. Serum 
levels of creatinine did not have significant variability during follow-up (3 months) and fever 
occurred mainly in the period between 24 and 48 h after the surgery.
Chang et al. [14] studied the systemic inflammation, coagulopathy and acute renal insuf-
ficiency following endovascular thoracoabdominal aortic aneurysm repair (TAAA). They 
hypothesized that endovascular TAAA repair triggers a severe form of PIS. During the post-
operative time, 18 of 38 patients (47%) developed fever (>38.0°C) and all had statistically sig-
nificant changes in leukocyte and platelet counts and prothrombin time. Once again, neither 
the definition nor the incidence was stated.
Georgiadis et al. [15] in their prospective study comparing the results of Endurant® endopros-
thesis in hostile and friendly necks, pointed to a PIS incidence of 36.4% (28 patients, 9 patients 
in friendly neck group vs. 19 patients in hostile neck group; p = 0.032) with a mean duration of 
2.02 days. However, the definition of PIS is unclear.
Two other studies described PIS incidence, but they did not clarify the definition used. 
Mazzaccaro et al. [16] performed a retrospective study with 10 patients who underwent EVAR, 
but only with Incraft® endograft. They found an incidence of PIS of 30% (three patients). 
However, they do not specify the definition that they used. Melissano et al. [17] evaluated 
retrospectively the safety and efficacy of the Zenith Alpha® (Cook Medical Inc., Bloomington, 
IN, USA), in thoracic endovascular aortic repair of thoracic aortic aneurysms, aortic ulcers and 
traumatic aortic rupture on 42 patients. They do not specify the PIS definition that they used 
but stated a PIS incidence of 2%.
Several studies defined PIS as a combination of two criteria: leukocytosis and fever. 
Arnaoutoglou et al. [1] performed a prospective study with 162 patients (148 with AAA and 
14 with TAAA) who underwent endovascular aneurysm repair. PIS was defined according 
to definition of SIRS: presence of fever (continuous temperature > 38°C) and leukocytosis 
(>12,000/μl) despite antibiotic therapy and negative culture results. PIS occurred in 49 patients 
(30.2%) and there were no significant differences in patients’ characteristics and intra-operative 
variables, between the two groups. In this study, the authors did not characterize the popula-
tion in detail and opted to describe consequences of PIS in six cases. In a subsequent prospective 
study of the same authors, with 40 patients, they found a similar incidence of PIS – 35% 
(14 patients). They did not also verify significant differences in patients’ characteristics and 
intraoperative variables. Of note, a significant increase in IL-6 levels was observed only in the 
PIS group and the decrease in platelets count was greater in the PIS group, as was an increase 
in hs-CRP. The incidence of PIS varied according to the graft that was deployed, with highest 
incidences for Anaconda grafts (Vascutek-Terumo Cardiovascular System Corp, Ann Arbor, 
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MI, USA) with 100% of incidence, and Zenith grafts (Cook Medical Inc., Bloomington, IN, 
USA), with 50% of incidence. The Talent grafts (Medtronic Vascular AVE, Medtronic Europe 
SA, Route du Molliau, Switzerland) had an incidence of 37% (6/16 patients) and the Excluder 
grafts (W.L. Gore & Associates, Inc., Flagstaff, AZ, USA) had the lowest incidence with 12% 
(2/17 patients) [4].
Dosluoglu et al. [6] studied the feasibility and safety of ambulatory percutaneous EVAR in a 
sample of 79 patients. In this way, they compared the group in which the patients go home in 
the same-day of the procedure to the non-ambulatory-group and evaluate the incidence of PIS 
in these two groups. They defined PIS as any combination of fever >37.8°C, white blood cell 
count >10.000/μl, abdominal and/or back pain, or other nonspecific symptoms such as malaise 
or loss of appetite. PIS occurred in 23% of the patients, 19% in the same-day discharge group 
and in 26% in non-ambulatory group.
In another study, with a retrospective design, of 118 patients who underwent EVAR but 
only with Anaconda endograft. These authors used the same definition of PIS with leuko-
cytes >12.000/μl and temperature and reported an incidence of PIS of 20.3% (24 patients) 
[8]. Another retrospective study with 87 patients, using the same definition for PIS, found 
an incidence of 39%. This value was not similar between graft types, with the highest inci-
dence for Anaconda endograft (71%) and the least incidence in Excluder grafts (13%) [18]. 
Arnaoutoglou et al. [10] prospectively evaluated PIS after elective EVAR in 214 patients 
with AAAs and investigated its association with clinical outcome during first 30 postopera-
tive days. The diagnosis of PIS occurred in 36% patients. They also used the same criteria 
described above for PIS.
With the same definition, Sartipy et al. [19] also investigated the impact of stent graft mate-
rial on the inflammatory response, in 45 patients undergoing standard elective EVAR. The 
global incidence of PIS was 28%. A single-center, observational cohort study of 204 consecu-
tive EVARs revealed an incidence of PIS of 31.4%, with the same definition [20]. In a similar 
way, Arnaoutoglou et al. [21] in a more recent prospective study with 182 consecutive EVARs, 
diagnosed PIS in 65 patients (35.7%).
Fewer studies defined PIS with elevation of CRP instead of leukocytosis. Voûte et al. [5] com-
pared the effect of stent graft composition in PIS. This group defined the PIS as fever (tym-
panic temperature > 38°C) and elevated serum CRP level (>10 mg/l). They found an incidence 
of PIS of 56.1% (46 patients) for the woven polyester group and 17.9% (12 patients) for the 
ePTFE group (p = 0.001).
A randomized, double-blind, placebo-controlled trial was designed to analyze the effect of 
a single preoperative dose of 30 mg/kg of methylprednisolone or placebo, administered 2 h 
before surgery, in reducing the incidence of PIS after EVAR. They used the SIRS criteria for PIS 
(the presence of at least two of the following criteria: temperature > 38°C or < 36°C; leukocytes 
>12.000/l, <4.000/ or > 10% bands; heart rate > 90; respiratory rate > 20; PaCO2 < 32 mm Hg), 
except the criterion of leukocytosis. Instead of leukocytosis, the criterion used was elevation 
of CRP > 75 mg/L. PIS with modified SIRS criteria was present in 27% in the methylpredniso-
lone group versus 100% in the placebo group [7].
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Gorla et al. [22] developed a retrospective study and analyzed PIS incidence, but the 133 patients 
included underwent TEVAR due to type B acute aortic syndrome. The authors defined PIS as 
fever >38°C, leukocytes >12.000/mL and CRP >10 mg/dL within 72 h after TEVAR, despite 
negative blood cultures. PIS was diagnosed in 15.8% of patients.
A German group studied the effects of antibiotics in preventing PIS after aortic endoprosthe-
sis implant. This trial included 40 patients and they did not have an aneurysmal disease. In 
each group, there were 18 type B dissections and 2 penetrating aortic ulcers.
They compared the influence of perioperative single-shot versus prolonged (7 days) antibi-
otic therapy on parameters of PIS after thoracic endografting. There were no differences in 
parameters related to PIS, namely body temperature, leukocytes count and CRP, between 
two groups. They also did not find differences between the groups of acute and chronic type 
B dissections [23].
Moulakakis et al. [11] assessed the inflammatory and renal response after TEVAR in the 
descending thoracic aorta on 30 patients (28 aneurysms, 1 type B aortic dissection and 1 pen-
etrating aortic ulcer). They do not evaluate the incidence of PIS but detected a significant 
increase in leukocytes, CRP, interleucin-6 and interleucin-10 at 24 and 48 h after endograft 
implantation compared to baseline; platelets were significantly decreased. This inflammatory 
response after TEVAR was associated to a rise in body temperature in the postprocedure 
period. Conversely, there were no significant differences in serum levels of interleucin-8, 
TNF-α, creatinine, urea or cystatin C after stent graft implantation.
In conclusion, many studies do not specify the PIS definitions, many others used the definition 
with leukocytosis and fever and only three studies used a definition that includes CRP. The 
reported incidences in literature vary greatly which is possibly a consequence of variability in 
definitions. Hence, the obvious need for a universal definition of this syndrome.
3. Etiology
The etiology of PIS is not entirely clear. Implant composition has been identified as one of the 
most important determinants of the incidence and severity of PIS. [4, 5] However, the inflam-
matory response is not of the same magnitude in all patients treated with the same type of 
endograft. So, factors other than implant material must also be responsible to the occurrence 
of PIS. These may be patient or implant related.
Lesion of the endothelium during implantation, bacterial translocation due to transient 
sigmoid ischemia, contrast medium-induced neutrophils degranulation, endovascular 
instrumentation of the mural thrombus and thrombosis of the aneurysm sac after aneu-
rysm exclusion had all been proposed as factors that could trigger the pathophysiology of 
PIS [14, 23–26] (Figure 1).
3.1. Endograft material
This is the best investigated risk factor; several studies compared the incidence of PIS or the 
difference in inflammatory parameters and endograft material, mainly focusing on differ-
ences between polyester and expanded politetrafluoroethylene (ePTFE)-based structures.
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The majority of the studies pointed to a higher incidence of PIS or a greater increase of inflam-
matory markers in polyester-based endografts [4, 5, 8, 18, 20]. Voûte et al. [5] constructed a 
multivariable risk model for PIS, and woven polyester constitution of the endograft was the 
only significant factor associated with an increased risk of developing PIS (HR 5.58; p = 0.007). 
Kakisis et al. [18] had similar results when testing for risk factors for PIS using a multivariable 
model; only the type of endograft was independently associated with the development of PIS.
Despite the results, another three studies could not identify a difference in the incidence of 
PIS between polyester and ePTFE endografts. [5, 11, 19] Gerasimidis et al. compared, prospec-
tively, the incidence of inflammatory response between endovascular aneurysm repair with 
polyester devices (12 patients) and ePTFE devices (10 patients). One patient in each group had 
PIS, according to SIRS criteria. Three patients in the polyester group had fever (>38°C) and 
only one patient in the PTFE group (p < 0.005). However, there were no statistically signifi-
cant differences between two groups, for all endpoints, possibly due to sample size. Of note, 
all the patients in this study received a dose of an antihistamine (cetirizine hydrochloride 
10 mg) before the surgery and nonsteroid antiinflammatory drugs (nimesulide 100 mg twice 
a day) during 72 h postoperatively [5]. In the study by Sartipy et al. [19] there were signifi-
cant differences between the two types of graft material concerning fever and CRP, but there 
were no significant differences in the number of PIS events. It could also be related to sample 
size, with 32 patients treated with polyester grafts but only 13 patients with ePTFE grafts. 
They performed a sensitivity analysis that showed if three more patients in the polyester 
group would have developed PIS (or none instead of one patient in the PTFE group), the 
results would have reached significance. Lastly, Moulakakis et al. [11] assessed the inflam-
matory and renal response after TEVAR, and they did not observe a significant difference in 
Figure 1. Multiple factors that may contribute to PIS occurrence.
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inflammatory response between polyester and PTFE groups. They attributed that to small 
number of patients implanted with ePTFE endografts in their trial.
In any case, PIS related to Anaconda® endografts had the highest incidence in published 
literature, except in one study by Nano et al. [8] in which the reported incidence was of only 
20.3% [4, 18, 25]. In that study, however, isolated fever without any sign of infection and 
maintained for more than a week occurred in many patients, even after administration of 
corticosteroids (median duration, 11 days, (4–30 days)). In the same period in this hospital, 
PIS occurred with other endografts but lasted for less than 3 days or resolved completely after 
administration of corticosteroids [8]. Thus, it seems that in addition to the higher incidence 
of PIS, Anaconda® endografts are associated to a more intense syndrome, which is also more 
difficult to resolve.
Apart from fabric, other components of the graft structure could be implicated. The stent 
structure, for example, could influence the occurrence of PIS. As discussed by Voûte et al. [5] 
when comparing Endurant® and Talent® endografts, the Excluder graft, which is associated 
to the lowest incidence of PIS, has an additional outer layer of ePTFE, covering the alloy, 
whereas in others, the metal and fabric are connected by stitches. Moreover, the latter have 
a bare top stent which constitutes an additional amount of nitinol directly exposed to the 
circulation and to the vessel wall. In addition to amount of alloy exposition, the exact balance 
between nickel and titanium (components of nitinol) or even the way of cutting and pol-
ishing may differ between manufacturers and may influence the inflammatory reaction [5]. 
However, it is important to note that nitinol has been widely used in coronary and peripheral 
arterial “bare-metal” stents and no inflammatory response have been reported in these appli-
cations [27]. In Zenith® endograft, an additional component of stainless steel can contribute 
for the inflammatory response, but this has not been adequately studied.
Delivery systems could also theoretically influence PIS. Moulakakis et al. [25] showed that the 
Excluder® endograft had a milder postimplantation inflammation, compared to the others. 
In addition to differences of material composition, the Excluder® endograft is introduced 
through a sheath, in contrast to other endografts. They hypothesize that this may cause 
less injury to endothelium. Moreover, thickness and porosity may differ between polyester 
endografts, as the metallic skeleton, and can justify variability in inflammatory response after 
EVAR [25]. Despite all the proposed mechanisms, the only component of endografts that 
seems to influence the incidence of PIS significantly is the fabric. Polyester, when compared 
to ePTFE, results in a higher inflammatory reaction both in vitro and in vivo, and this is well 
replicated in aortic endograft implants [28].
3.2. Thrombus
The hypothesis that the amount of preexisting mural thrombus within the aneurysm sac 
could be related to PIS development derived from the finding that mural thrombus of an 
aortic aneurysm contains high levels of interleucin-6 [29]. In this way, it was conjectured that 
manipulations with endovascular material, as wires and catheters, in mural thrombus could 
release interleucin-6 and induce an inflammatory response. Nano et al. [8] reported an asso-
ciation between preoperative thrombus thickness and PIS with EVAR using the Anaconda® 
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endograft (p = 00.1). However, Kakisis et al. [18] rebutted this hypothesis, since they found that 
the volume of chronic mural thrombus did not affect any parameter of PIS. In the same line, in 
the study by Moulakakis et al. [25] the Anaconda® endograft had the highest inflammatory 
response and, simultaneously, requires less thrombus manipulation with catheters and wires 
during implant, once it has a magnet on the contralateral limb to facilitate its cannulation. If 
the mural thrombus was the main source to PIS, patients treated with the Anaconda® endo-
graft should have the lowest incidence, and the contrary is observed.
Another hypothesis was that new-onset thrombus, instead of chronic mural thrombus, could 
be responsible for the acute inflammatory response [30]. Three authors tried to demonstrate 
this effect of new-onset thrombus but the results were not consistent. Kakisis et al. [18] could 
not find an association between the previous thrombus and PIS, but they found a significant 
correlation between the volume of new-onset thrombus and PIS parameters. In a multiple 
variable model, these authors showed that both the volume of new-onset thrombus and the 
type of endograft were independently associated with the development of PIS. However, 
Vôute et al. [5] analyzed the association between inflammatory response and new-onset 
thrombus after EVAR and found no significant correlation between new-onset thrombus and 
the rise in temperature (p = 0.08) or CRP (p = 0.17), with a larger patient sample. In the same 
way, Arnaoutoglou et al. [10] did not find differences regarding preoperative endoluminal 
thrombus or in the amount of newly formed thrombus between PIS and non-PIS patients 
groups. In light of the current evidence, it is not likely that chronic mural thrombus or new-
onset thrombus within the aneurysm sac play a significant role in the development of PIS. It 
is possible that new onset thrombus may play a small role, which could not yet be clearly 
demonstrated due to sample size in all published studies on the subject.
3.3. Bacterial translocation
Another potential etiology for PIS after endovascular aneurysm repair is bacterial transloca-
tion due to transient sigmoid ischemia. Intestinal ischemia may be produced by either occlu-
sion of a previously patent inferior mesenteric artery (IMA) or microembolization during 
catheter and wire manipulations. Thus, Kakisis et al. [18] analyzed the association between 
patency of the IMA and the postoperative temperature and inflammatory markers and found 
no significant correlation. Another trial, that studied the effects of antibiotic therapy in PIS 
after thoracic aortic stent placement, is in agreement [23]. The authors stated that there were 
no differences in parameters related to PIS, regardless of the duration of postoperative anti-
biotic therapy. Therefore, the hypothesis of bacterial translocation as a cause for PIS seems 
remote and there is no evidence to date to support it.
3.4. Contrast
Videm et al. [26] suggested that contrast medium iohexol provokes neutrophil degranulation, 
which is greatly enhanced when combined with stent graft material, contributing to PIS occur-
rence. There are other recent studies that specifically analyzed inflammatory response after 
endovascular aortic repair; however, they did not find any correlation between contrast use 
or dosage and PIS parameters [5, 8, 18, 25]. As such, this theory remains to be demonstrated.




The influence of several other factors in PIS parameters has also been explored, namely age, 
gender, aneurysm size, extent of aortic coverage, length of operation, blood loss or transfu-
sion, intensive care unit, statin, chronic obstructive disease, ischemic heart disease and heart 
failure. None has been shown to be an important factor to PIS [5, 8, 9, 14, 18].
4. Manifestations and diagnosis
PIS is characterized by fever, anorexia, fatigue and lumbar pain associated to increase in leu-
kocytes count, CRP, decrease in platelets count and/or coagulation abnormalities.
It typically resolves within 2 weeks without any permanent ill effects, but in some cases may 
result in severe complications such as pulmonary dysfunction, cardiovascular events, renal 
insufficiency and multisystem organ failure [1, 14, 25].
The diagnosis might be suspected in the presence of fever without clinical source of infection 
in the immediate postoperative period after EVAR. However, the diagnosis of PIS will depend 
on definition that is adopted.
Fever is usually accompanied by a rise in laboratorial inflammatory markers and a drop in 
platelet count. Leukocytes count typically rises in the first postoperative day [5, 25]. CRP 
levels increase significantly between the first and third postoperative day [23, 31] (Figure 2).
In the presence of fever and inflammatory parameters in the early postoperative period, 
patients usually undergo a work-up for possible infection, typically including chest radiogra-
phy, urinalysis, urine culture and blood culture [32]. Some argue that this may be costly and 
unnecessary in clinical absence of an infection source [33]. However, since consequences of a 
serious postoperative infection may be devastating, at least close observation is recommended.
Figure 2. Evolution of body temperature, leucocytes count and CRP since EVAR until 96 h after the procedure. Adapted 
by Voûte et al. [5], Gabriel et al. [13] and Akin et al. [23].
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Sartipy et al. [9] designed a prospective study to test the hypothesis was that procalcitonin 
would remain <0.5 ng/mL among patients who develop PIS after elective EVAR surgery, 
conversely to infectious complications. They defined PIS as a body temperature > 38°C and 
leukocytes >12,000/mL at any time during the observation period combined with no other 
detected complication or any open surgical event explaining the inflammatory response. The 
global incidence of PIS in this trial was 17.5% (12 patients) but this incidence was higher in 
patients with polyester grafts than in PTFE grafts (22.4% vs. 5%). They verified that all PIS 
patients had levels of procalcitonin <0.5 ng/mL, as they hypothesized, whereas all showed an 
elevation on CRP >100 mg/L and leukocytes >12.000/mL.
Thus, procalcitonin appears as a good differentiator between PIS and infectious complica-
tions, probably less expensive and faster than microbiologic culture tests.
5. Clinical consequences
Several clinical consequences of PIS have been proposed, both in the early postoperative 
period and over follow-up (Table 2).
5.1. Prolongation of hospital stay/readmissions
Moulakakis et al. [11] did not find any clinical adverse events related to PIS and there were 
no readmissions in their study. In another study that evaluated inflammatory response to 
Anaconda® endografts, the patients who developed this syndrome had a longer hospital-stay 
[8]. Other studies showed a significant prolongation of postoperative hospitalization in the 
PIS group compared to non-PIS group [4, 10, 20].
Arnaoutoglou et al. [1] described six cases that required readmission, four cases due to a mild 
SIRS that resolves with non-steroidal anti-inflammatory drug orally, but the other two cases 
were a severe SIRS that required a stay in an intensive care unit and endovenous corticoste-
roids treatment.
In a study concerning the applicability of percutaneous ambulatory EVAR, one patient was 
also readmitted due to severe PIS in third postoperative day (in the non-ambulatory group) 
and PIS was the only reason for delayed discharge in five patients [6].
5.2. Renal dysfunction
Chang et al. [14] analyzed the systemic inflammation, coagulopathy and acute renal insuf-
ficiency following endovascular TAAA repair. These authors found that patients with 
postoperative renal insufficiency had higher changes in leukocytes and platelets counts, as 
compared with those who did not develop renal failure. Indeed, the two patients who died 
in first postoperative month developed acute renal insufficiency in the early postoperative 
period. The preoperative glomerular filtration rate < 60 mL/min/1.73 m2 was not associated 
with the development of acute renal insufficiency (p = 0.80). They performed a univariate 
logistic regression analysis, which showed that each 5000 cells/μL increase in leukocytes in 
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the postoperative period was associated with a 2.4-fold odds of postoperative renal insuf-
ficiency (p = 0.02). For platelets, each decrease of 50,000 platelets/μL was associated with a 
4.0-fold odds of postoperative renal insufficiency (p = 0.02). In opposition, Moulakakis et al. 
[11] stated that renal function was not influenced by the inflammatory response; no correla-
tion was recognized between the increased inflammatory markers and renal function.
5.3. Cardiovascular events
In a study that analyzed the influence of inflammatory reaction after endovascular aneurysm 
repair in 30-day outcomes, a multiple logistic regression model revealed that coronary artery 
disease (p = 0.01), post-operative hs-CRP (p = 0.001) and duration of fever (p = 0.02) inde-
pendently predict major cardiovascular events. For every additional day of fever after the 
first, the chance of a cardiovascular episode increased by 67.9% (p = 0.017) and for every 
10 units increase of hs-CRP, this probability increases by 15% (p = 0.001). For all adverse 
events studied, namely cardiovascular events, acute renal failure, readmission and death by 
any cause, multiple logistic regression analysis showed that postoperative hs-CRP (p = 0.004), 
PIS (p = 0.01), maximum temperature (p = 0.02) and smoking history (p = 0.02) were indepen-
dent predictors. Postoperative hs-CRP revealed an important predictor for adverse outcomes 
during the first 30 days. A threshold value of 125 mg/L was highly associated with an adverse 
event, with a sensitivity of 72% and specificity of 75% [10].
In a prospective study of 182 consecutive EVARs, patients were monitored during a year. 
Several adverse events are scrutinized, such as any major adverse cardiovascular events, 
acute renal failure, readmission and death from any cause. During the follow-up period, 
major adverse cardiovascular events occurred in 17.2% patients in PIS group vs. 4.3% in non 
PIS group and the other adverse events occurred in 18.8% of patients vs. 5.1%, respectively. 
Table 2. Summary table of the studies that favor influence of PIS in outcomes and of those that are against.
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Multiple logistic regression analysis showed that the occurrence of PIS was the only inde-
pendent predictor of major adverse cardiovascular events (p = 0.007) or any adverse event 
(p = 0.005). Patients with the diagnosis of PIS were about 4–5 times more likely to suffer of a 
major cardiovascular event or another adverse event, than non-PIS patients [21].
Conversely, Kwon et al. [20] stated that patients with and without PIS had similar long-
term overall survival rates and other clinical outcomes, such as systemic or implant-related 
complications.
5.4. Endoleaks
In the study by Voûte et al. [5] the change in PIS parameters did not correlate to postoperative 
endoleaks. Besides prolongation of hospital stay, Nano et al. [8] also established a benign 
character for the PIS; no association between PIS and onset of early and long-term complica-
tions, namely endoleaks, was reported.
Gorla et al. [22] studied a composite endpoint of major adverse events, such as aortic rupture, 
need for reintervention and all-cause mortality, after TEVAR of type B acute aortic syndromes. 
The mean follow-up was 4.0 ± 2.9 years. The major adverse events were more frequent in the 
PIS than in the non-PIS group (62.5 vs. 25.9%; p = 0.004).
Kwon et al. [20] in a study with a follow-up of 44 months, PIS was significantly associated 
with a decreased risk of developing type II endoleaks (p = 0.044). PIS appeared to be beneficial 
in preventing type II endoleaks during postoperative period. Kaplan–Meier survival analysis 
showed that the groups (PIS and non-PIS) had similar rates of overall survival (p = 0.761) and 
other clinical outcomes (p = 0.562), except the rate of secondary procedures that was signifi-
cantly higher in the non-PIS group (p = 0.049).
Arnaoutoglou et al. [21] in a prospective study with 1 year-follow up, found no correlation 
between endoleak or any complication rates and PIS (p > 0.05).
5.5. Quality of life
The analysis of the questionnaires on quality of life after 1 month of the surgery showed that 
PIS patients felt significantly more limited in their daily physical activities after surgery, as 
well as more emotionally discouraged and depressed/anxious about their state of health [8]. 
No long-term studies involving quality of life are available to date.
In summary, there is a suspicion that PIS may be involved in a higher rate of early cardiovas-
cular complications and worse early quality of life. There is no evidence to date that suggests 
a worse long-term outcome for patients affected, but the data are scarce.
6. Prevention and treatment
The 30 day-outcomes of patients with PIS described by Arnaoutoglou et al. [10] suggest that 
a specific treatment should be adopted to PIS to avoid clinical consequences. Akin et al. [23] 
tested the extension of antibiotherapy during the postoperative time, but it did not show 
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any advantage in PIS incidence. In the study by Nano et al. [8] in case of PIS diagnosis, 1 g of 
hydrocortisone was administered intravenously on the third postoperative day, according to 
institutional protocol. In another study with patients who underwent percutaneous ambula-
tory EVAR, one patient had to be readmitted due to a severe PIS in third postoperative day. 
He was managed with hydration, pain control and anti-inflammatory medications and went 
home again after 3 days [6].
De la Motte et al. [7] in a randomized, double-blind, placebo-controlled trial involving 153 patients, 
analyzed the effects of a single preoperative dose of 30 mg/kg of methylprednisolone or pla-
cebo, administered 2 h before surgery. For diagnosis of PIS, they used all criteria of SIRS, except 
for leukocytosis that was changed to CRP elevation due to the influence of corticoid therapy 
on leucocyte count and they obtained, with a single preoperative dose of methylprednisolone, 
a reduction in PIS from 100–27% [7]. The postoperative need for morphine was significantly 
reduced by methylprednisolone but the need for antiemetics was similar. There were no dif-
ferences in 30-day medical morbidity (13 vs. 43%), surgical morbidity (20 vs. 43%), reinterven-
tions (0 vs. 29%) or readmissions (7 vs. 14%) in the methylprednisolone versus placebo group. 
There was no 30-day mortality in all the patients included, and during the 3 months of follow 
up, there was no significant difference in mortality between the groups (3% vs. 1%, P = 1.0). 
Regarding adverse effects of corticosteroids, 11 potential methylprednisolone side effects 
occurred in 10 patients (14%). They were mainly related to infusion of the drug: metallic taste 
in five patients, flushing in three patients, rise in blood pressure requiring treatment in two 
patients and euphoria within the first 24 h in one patient. In the placebo group, rise in blood 
pressure was noted in one patient. Analyzing the subgroup of diabetic patients (15 patients in 
methylprednisolone group and 7 patients in placebo group), the intraoperative median blood 
glucose levels were higher in the methylprednisolone group than in the placebo (363 mg/dL 
vs. 298 mg/dL (p = 0.01)) and they remained higher during the first 24 h (p = 0.006). In 47% of 
patients in the methylprednisolone group, supplementary insulin was necessary compared to 
none in placebo group during the first 24 h. There were no records of adverse events relating 
to dysregulation of blood glucose levels. Subgroup analysis on the diabetic patients showed 
the same tendencies as in the entire cohort [7]. In this trial, there was a substantial difference 
between PIS incidence with a single preoperative dose of methylprednisolone. However, they 
Figure 3. Schematic diagram of prevention, diagnosis and treatment of PIS, with associated references.
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defined PIS as having either fever or elevated CRP levels. Hence, possibly, the higher incidence 
of 100% in placebo group.
The routine administration of drugs like steroids or nonsteroid anti-inflammatory drugs is of 
concern because of their side effects, mainly in patients with multiple or more severe comor-
bidities [1]. However, it seems reasonable to prevent this inflammatory response, once it can 
lead to prolonged hospitalization or a readmission and even to more severe consequences, as 
the authors described above.
Undoubtedly, future studies have to be performed to clarify the need for routine prophylaxis 
for this syndrome or a symptom based anti-inflammatory therapy (Figure 3).
7. Conclusion
The absence of a universal definition for PIS is responsible to the variability of its incidence. 
However, CRP seems to be a better criterion for PIS instead of leukocyte count. The etiology 
is still not clarified, but the majority of the studies pointed to a relevant role for endograft 
material. Regarding diagnosis, procalcitonin appears to be a good differentiator between PIS 
and infectious complications. The clinical consequences of this syndrome, in length of hos-
pital stay, readmissions, renal function, cardiovascular events, endoleaks and quality of life, 
are not fully elucidated, and more studies have to be performed. However, there is evidence 
suggesting a prolonged hospital stay, higher risk of early cardiovascular events and worse 
early quality of life for affected patients. Regarding treatment, although corticosteroids and 
nonsteroidal anti-inflammatory drugs seem to be a reasonably effective strategy, there is a 
need to establish the best treatment and weather pharmaceutical prophylaxis is necessary. 
The routine administration of drugs like steroids or nonsteroid anti-inflammatory drugs 
raises concerns due to side effects, mainly in patients with more severe comorbidities.
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